Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs

Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs

Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313

Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD – Optimum Strategic Communications

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody targeting TSLP ligand as well as building a discovery pipeline of long-acting bispecifics Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, to join the Windward […]

Timberlyne Therapeutics Raises $180M in Series A Funding

Timberlyne Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company focused on the development of new therapies for autoimmune disorders, raised $180M in Series A funding. The round was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Health Investment. The company […] The post Timberlyne Therapeutics Raises …

Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs - Pipelinereview

Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313 Financing co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners SAN DIEGO, CA, USA I January 9, 2025 I Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the …